IP50-28: Quality care measures among patients with high-risk non-muscle invasive bladder cancer with papillary carcinoma or carcinoma in situ receiving front-line Bacillus Calmette-Guérin or other intravesical therapies

IP50-28: Quality care measures among patients with high-risk non-muscle invasive bladder cancer with papillary carcinoma or carcinoma in situ receiving front-line Bacillus Calmette-Guérin or other intravesical therapies

Sunday, May 17, 2026 7:00 AM to 9:00 AM · 1 hr. 59 min. (America/New_York)

146A

Abstract

Speakers

Mukul Singhal

Director, US RWV&EJohnson and Johnson

Sessions

IP50: Bladder Cancer: Non-invasive IV

Sunday, May 17, 2026 7:00 AM to 9:00 AM

Christopher Anderson · Columbia University Medical Center

William Tabayoyong · Department of Urology

Mary Westerman · Department of Urology, University of North Carolina

Registered attendees

Scott Flanders

VP of Medical AffairsImmunityBio, Inc.

Log in

See all the content and easy-to-use features by logging in or registering!